Related Experiment Videos
Chylothorax after heart/lung transplantation.
Tomasz M Ziedalski1, Thomas A Raffin, Daniel Y Sze
1Division of Pulmonary and Critical Care Medicine, Stanford University Medical Center, Stanford, California 94305, USA.
Summary
Chylothorax, a complication of lung transplants, can be managed with various treatments. This study explores medical and surgical options, including a novel use of aminocaproic acid to reduce lymph flow.
Area of Science:
- Cardiovascular Sciences
- Thoracic Surgery
- Transplantation Medicine
Background:
- Chylothorax is a significant complication following lung and heart-lung transplantation.
- Managing post-transplant chylothorax requires careful consideration of multiple therapeutic strategies.
Observation:
- This article details the clinical course of three heart-lung allograft recipients who developed chylothorax.
- The study observed the effectiveness of various management interventions in these patients.
Findings:
- Management options discussed include dietary changes, octreotide, thoracic duct interventions, and surgical pleurodesis.
- Aminocaproic acid was explored as a novel agent to decrease lymphatic flow.
Implications:
- A multidisciplinary approach integrating medical and surgical interventions is proposed for optimal chylothorax management.
- These findings contribute to refining treatment protocols for post-transplantation chylothorax.